348 related articles for article (PubMed ID: 3171974)
1. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
[TBL] [Abstract][Full Text] [Related]
2. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
3. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
4. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes.
Kim M; Shen DD; Eddy AC; Nelson WL; Roskos LK
Drug Metab Dispos; 1993; 21(2):309-17. PubMed ID: 8097702
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
7. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4--implications for susceptibility to Parkinson's disease.
Coleman T; Ellis SW; Martin IJ; Lennard MS; Tucker GT
J Pharmacol Exp Ther; 1996 May; 277(2):685-90. PubMed ID: 8627546
[TBL] [Abstract][Full Text] [Related]
8. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
9. Metabolic kinetics of pseudoracemic propranolol in human liver microsomes. Enantioselectivity and quinidine inhibition.
Marathe PH; Shen DD; Nelson WL
Drug Metab Dispos; 1994; 22(2):237-47. PubMed ID: 8013280
[TBL] [Abstract][Full Text] [Related]
10. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6.
Mautz DS; Nelson WL; Shen DD
Drug Metab Dispos; 1995 Apr; 23(4):513-7. PubMed ID: 7600921
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
12. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Tyndale RF; Inaba T; Kalow W
Drug Metab Dispos; 1989; 17(3):334-40. PubMed ID: 2568917
[TBL] [Abstract][Full Text] [Related]
13. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1996 Jul; 278(1):21-30. PubMed ID: 8764331
[TBL] [Abstract][Full Text] [Related]
14. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
16. Catalyzation of cocaine N-demethylation by cytochromes P4502B, P4503A, and P4502D in fish liver.
Arinç E; Bozcaarmutlu A
J Biochem Mol Toxicol; 2003; 17(3):169-76. PubMed ID: 12815613
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs.
Koyama E; Chiba K; Tani M; Ishizaki T
J Pharmacol Exp Ther; 1997 Jun; 281(3):1199-210. PubMed ID: 9190854
[TBL] [Abstract][Full Text] [Related]
18. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
19. Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism.
Muralidharan G; Midha KK; McKay G; Hawes EM; Inaba T
Xenobiotica; 1989 Feb; 19(2):189-97. PubMed ID: 2786289
[TBL] [Abstract][Full Text] [Related]
20. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
